G.R. No. 217872, April 26, 2017
ALFI, ET AL. V. GARIN, ET AL.

FACTS

This case involves a challenge to the certification and re-certification of certain contraceptive products by the Food and Drug Administration (FDA) under the Reproductive Health Law. The petitioners opposed the FDA’s actions, arguing that the agency violated its own procedures by failing to address their submitted comments during the re-certification process. The core procedural dispute centered on whether the FDA’s process for determining if a contraceptive is non-abortifacient requires a public hearing or formal adjudication.
The FDA, as the regulatory body, follows a detailed, technical process for product registration and certification. This involves the Center for Drug Regulation and Research reviewing extensive scientific data, including formulation details, stability studies, and clinical trial results, before issuing a Certificate of Product Registration. The petitioners contended that their public comments on specific contraceptives were ignored, depriving them of participation in a process with significant public health implications.

ISSUE

The primary issue is whether the FDA’s certification and re-certification proceedings for determining the non-abortifacient nature of contraceptives require a public hearing or the exercise of quasi-judicial functions.

RULING

The Concurring Opinion clarifies that while the FDA violated its own procedures by not acknowledging or addressing the petitioners’ comments, a certification proceeding is not a quasi-judicial function requiring a trial-type hearing. The FDA’s role in these proceedings is purely regulatory and scientific. It involves applying legal standards to technical and pharmacological data to assess a product’s safety, efficacy, and non-abortifacient character. This task does not involve adjudicating the rights between opposing parties in a contentious manner.
The legal logic is that the FDA acts administratively, not judicially, in these certifications. Its mandate is to ensure public health through scientific evaluation, not to resolve a legal dispute. However, public participation through the submission of comments remains crucial for transparency and accountability, allowing the public to scrutinize government action. Thus, the FDA’s failure to respond to submitted oppositions was a procedural misstep, but the nature of the proceeding itself does not constitutionally mandate a formal public hearing. The process is designed for technical review, not for the adversarial presentation of evidence typical of a quasi-judicial body.